Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  MedicationType 2 DiabetesIssue 611

FDA Approves Eli Lilly Diabetes Combo Drug Jentadueto

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced the FDA approved Jentadueto™ (linagliptin/metformin hydrochloride) tablets....

Advertisement

Drawing from the momentum of Tradjenta™ (linagliptin) tablets -- approved for U.S. marketing in May 2011 – JENTADUETO combines linagliptin and metformin into a new, single-tablet option, taken twice daily and comes in 3 different dosages.

JENTADUETO is a prescription medication used along with diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both linagliptin and metformin is appropriate. JENTADUETO is not for the treatment of type 1 diabetes or diabetic ketoacidosis (increased ketones in the blood or urine). It has not been studied in combination with insulin.

At the maximum dose, JENTADUETO demonstrated placebo-corrected reductions in hemoglobin A1Clevels of up to 1.7 percent. It can be used alone or in combination with a sulfonylurea, another commonly prescribed medication for type 2 diabetes.

The JENTADUETO label contains a boxed warning because the addition of metformin which may cause a rare but serious condition called lactic acidosis (a build-up of lactic acid in the blood) that can cause death. It is not for treatment of type 1 diabetes or diabetic ketoacidosis and has not been studied in combination with insulin. The dosage should be individualized based on the patient's current regimen and the maximum recommended dose is 2.5 mg linagliptin/1000 mg metformin twice a day. It should be given twice daily with meals, with gradual dose escalation to reduce the gastrointestinal side effects due to metformin.

It comes in 3 dosage forms, 2.5 mg linagliptin/500 mg metformin hydrochloride, 2.5 mg linagliptin/850 mg metformin hydrochloride and 2.5 mg linagliptin/1000 mg metformin hydrochloride.

Contraindications include: renal impairment, metabolic acidosis and hypersensitivity to linagliptin or metformin.

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company news release

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 01 February, 2012 and appeared in  MedicationType 2 DiabetesIssue 611

Past five issues: Diabetes Clinical Mastery Series Issue 233 | SGLT-2 Inhibitors Special Edition March 2015 | Issue 773 | Diabetes Clinical Mastery Series Issue 232 | GLP-1 Special Editions March 2015 |

2015 Most Popular Articles:

FDA Approves Sanofi's Diabetes Drug Toujeo
Posted February 27, 2015
One Modification of Diet Can Improve the Metabolic Syndrome
Posted February 27, 2015
Eylea Bests Avastin, Lucentis in Diabetic Macular Edema
Posted February 27, 2015
'Smart' Insulin Holds Promise for Type 1 Diabetes Patients
Posted February 27, 2015
What Most Docs Don't Do: Counsel Patients on Drug Adherence
Posted February 27, 2015
Reduced GLP-1 Precedes Type 2 Diabetes
Posted March 05, 2015
Resistance Exercise after Dinner Decreases CVD Risk for Type 2's
Posted February 27, 2015
Breastfeeding May Lower Risk of Type 1 Diabetes
Posted February 27, 2015
Quality Management in Diabetes Care
Posted February 27, 2015
Custom Mobile App for Nurses Diagnoses More Obesity, Smoking and Depression
Posted February 27, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Are you interested in learning how to improve patient care by doing a reimbursable comprehensive diabetic foot exam?
CME/CE of the Week
Presented by CardioCareLive
Category: Cardiology



Search Articles On Diabetes In Control